Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Van Hout

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Kidney International. Supplement|January 4, 1998
Economic evaluation of benazepril in chronic renal insufficiencyB A van Hout, G P Simeon, J McDonnell, et al.
Journal of Internal Medicine|August 18, 2000
Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch womenC J Moerman, B A Van Hout, L Bonneux, et al.
Pharmacoeconomics|April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic modelB A van Hout, G Wielink, G J Bonsel, et al.
American Heart Journal|April 16, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 17, 1996
[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control]C E de Laet, B A van Hout, A Hofman, et al.
Journal of Health Economics|January 6, 2000
Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5DJ J Busschbach, J McDonnell, M L Essink-Bot, et al.
Journal of Managed Care & Specialty Pharmacy|May 24, 2017
The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision MakingA Reginald Waldeck, Marc F Botteman, Richard E White, et al.
Health Economics|September 1, 1994
Costs, effects and C/E-ratios alongside a clinical trialB A van Hout, M J Al, G S Gordon, et al.
Health Economics|July 31, 1998
Sample size calculation in economic evaluationsM J Al, B A van Hout, B C Michel, et al.
Public Health Nutrition|May 3, 2013
Effects of salt labelling and repeated in-home consumption on long-term liking of reduced-salt soupsAstrid A Willems, Danielle H A van Hout, Nicolien Zijlstra, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Kidney International. Supplement|January 4, 1998
Economic evaluation of benazepril in chronic renal insufficiencyB A van Hout, G P Simeon, J McDonnell, et al.
Journal of Internal Medicine|August 18, 2000
Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch womenC J Moerman, B A Van Hout, L Bonneux, et al.
Pharmacoeconomics|April 8, 1993
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic modelB A van Hout, G Wielink, G J Bonsel, et al.
American Heart Journal|April 16, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Nederlands Tijdschrift Voor Geneeskunde|August 17, 1996
[Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control]C E de Laet, B A van Hout, A Hofman, et al.
Journal of Health Economics|January 6, 2000
Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5DJ J Busschbach, J McDonnell, M L Essink-Bot, et al.
Journal of Managed Care & Specialty Pharmacy|May 24, 2017
The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision MakingA Reginald Waldeck, Marc F Botteman, Richard E White, et al.
Health Economics|September 1, 1994
Costs, effects and C/E-ratios alongside a clinical trialB A van Hout, M J Al, G S Gordon, et al.
Health Economics|July 31, 1998
Sample size calculation in economic evaluationsM J Al, B A van Hout, B C Michel, et al.
Public Health Nutrition|May 3, 2013
Effects of salt labelling and repeated in-home consumption on long-term liking of reduced-salt soupsAstrid A Willems, Danielle H A van Hout, Nicolien Zijlstra, et al.
Pageof 12